



Treatment completion marks milestone in Phase 2 clinical trial

Brisbane, Australia, 4th October 2018: An important milestone in Factor Therapeutics' Phase 2 clinical trial for venous leg ulcer healing was reached overnight, with the final patient completing treatment in the US.

The last treatment visit, part of the trial known as VF00102, was conducted slightly ahead of schedule. The company is now moving ahead with final quality checks and database analysis before the expected release of top-line results in mid-November.

"We're delighted to have reached this important milestone, and want to offer a huge 'thank you' to all of our patients for agreeing to be part of the trial," said Dr Ros Wilson, Factor Therapeutics' CEO.

"This completion means we are now only a few weeks away from readout. In the meantime, our partnering discussions and preparations for regulatory interactions in Europe and the US next year are continuing," she said.

-ENDS-

Contact for Further Information:

Dr. Rosalind Wilson
Chief Executive Officer
Factor Therapeutics Limited
r.wilson@factor-therapeutics.com

About Factor Therapeutics

Factor Therapeutics Limited ("Factor") is a biomedical technology company that is developing treatments for acute and chronic wound healing applications. Factor is a clinical stage company with its lead program (VF-001) in Phase II for the treatment of venous leg ulcers (VLUs). The company is also developing solutions for a variety of interventional wound care and serious orphan dermatology conditions. The company's platform technology originates from the Institute of Health and Biomedical Innovation at the Queensland University of Technology (QUT), Australia. Factor's shares are traded on the Australian Securities Exchange (ASX) under the ticker FTT. For more information, please visit <https://factor-therapeutics.com>